



(Nasdaq: ZIVO)

Transformative Opportunities in Therapeutics & Nutrition

January 2023



SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

Some of the statements contained in this presentation are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements involve known and unknown risks, uncertainties and other factors which may cause our or our industry's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements include, but are not limited to statements regarding:

- The Company's ability to raise the funds we need to continue our operations;
- The Company's goal to begin to generate revenues and become profitable;
- Regulation of our products;
- Market acceptance of our products and derivatives thereof;
- The results of current and future testing of our products;
- The anticipated performance and benefits of our product;
- The Company's ability to expand its intellectual property;
- The Company's ability to enter into strategic partnerships;
- The Company's ability to generate licensing fees; and
- The Company's financial condition or results of operations

In some cases, you can identify forward-looking statements by terms such as "may", "will", "should", "could", "would", "expects", "plans", "anticipates", "believes", "estimates", "projects", "predicts", "potential" and similar expressions intended to identify forward looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance, or achievements expressed or implied by such forward-looking statements. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Also, these forward-looking statements represent our estimates and assumptions only as of the date of this report. Except as otherwise required by law, we expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statement contained in this presentation to reflect any change in our expectations or any change in events, conditions or circumstances on which any of our forward-looking statements are based. We qualify all of our forward-looking statements by these cautionary statements.

THE INFORMATION IN THIS PRESENTATION IS PROVIDED TO YOU SOLELY FOR INFORMATIONAL PURPOSES AND IS NOT AN OFFER TO BUY OR SELL, A SOLICITATION OF AN OFFER TO BUY OR SELL, ANY SECURITY OR INSTRUMENT OF THE COMPANY, OR TO PARTICIPATE IN ANY INVESTMENT ACTIVITY OR TRADING STRATEGY.



One Natural Source. Numerous Value-Driving Opportunities.

Developing novel therapeutic candidates and nutritional functional food ingredients to power immune health



Near-Term Revenue:

- Via out-licensing IP for a product candidate for the treatment of coccidiosis in poultry
- Commercializing an algae nutritional supplement for the human green powder and vegan protein markets



Long-term Valuation Multiplier:

- Published studies demonstrate an active therapeutics pipeline addressing billion-dollar opportunities in animal and human disease treatment through immune and other novel pathways
- Multi use nutritional ingredient in various foods for animals and humans



Robust and Versatile Products:

- Various commercial applications in animal feed, functional and medical foods, dietary supplements, nutraceuticals and pharmaceuticals

- ✓ Patent-pending use as an immune modulating candidate which may establish a new class of therapeutic products
- ✓ Potentially numerous therapeutic applications across three global mega-markets: human, livestock, and companion animals.



Zivo Bioscience, Inc. – At a Glance



One Natural Source. Numerous Value-Driving Opportunities.



Therapeutics (biotech)

- Isolation, identification and development of extracts, fractions, or molecules derived from proprietary algal polyculture
- For use in the treatment of disease or other health conditions in humans and animals.
- Protected by patents or trade secrets.
- Monetized through licensing, joint venturing, or other structures to leverage established product development, manufacturing and sales and distribution capabilities.



Nutrition (agtech)

- Growth and distribution of Zivo's proprietary whole algal biomass for use as a food or food ingredient to take advantage of its unique nutritional characteristics.
- The identified components of our algae allow many potential structure-function claims for nutrition and overall health enhancement.
- Implementation of the nutritional strategy through ZIVOLife subsidiary.
 - This opens the door for specific investment for the growing of algae, product development, and sales and distribution of whole algae products.



Significant Market Opportunity in Therapeutic Markets

Novel active compounds have broad applicability for treatment of disease



Poultry Study Results

Performed twenty poultry studies to evaluate the efficacy in the treatment of coccidiosis

Validated efficacy and mechanism of action studies in poultry gut health:

- ✓ Minimized or eliminated negative effects of coccidiosis on growth performance and digestive health
- ✓ Reduced incidence of *Campylobacter*, *Salmonella*, *E. coli*, and *C. perfringens* in digestive tracts

Currently being independently validated by a global animal pharma company



Commercial Application

Therapeutic additive designed to be introduced in poultry feed or drinking water – IP protected via global patent strategy

Potential as a replacement for antibiotics, ionophores, and other chemical-based treatments

Joint development agreement and / or license negotiations upon successful third-party validation



Market Opportunity

\$10 billion

Worldwide annual cost of coccidiosis in poultry

\$5.8 billion by 2027

Worldwide animal antimicrobials market

\$753M in 2020 → \$1.1B by 2025

Global feed phytogenic market size growth

\$14.6B in 2020 → \$23.9B by 2028

Global animal growth promoters and performance enhancers market size growth

Therapeutic Long Term Opportunities

ZIVO intends to evaluate additional therapeutic opportunities and will employ a business model to license its proprietary molecules or bioproducts to monetize its intellectual property portfolio across multiple applications


Poultry Other (Livestock)	Porcine (Livestock)	Bovine (Livestock)	Canine (Companion)	Human
Therapeutic Opportunities <ul style="list-style-type: none"> • Avian flu • Necrotic enteritis • Foodborne gut pathogens 	Therapeutic Opportunities <ul style="list-style-type: none"> • Respiratory disease • Digestive health 	Therapeutic Opportunities <ul style="list-style-type: none"> • Mastitis 	Therapeutic Opportunities <ul style="list-style-type: none"> • Joint health 	Therapeutic Opportunities <ul style="list-style-type: none"> • Joint health • Anti-aging / Skin health • Sepsis

✓ Monetization via partnering with established pharma companies.

✓ Joint develop agreements (JDA) as needed.

✓ IP license leading to a long-term, high quality annuity stream of income for Zivo.

Due to the nature of the IP and the various applications, Zivo may plan to develop individual licenses for each application in each target species.



Animal Market Annualized:

Vaccines - \$9.2 billion

Phylogenics - \$0.8 billion

Eubiotics - \$3.9 billion

Human Market Annualized:

Antibiotics - \$40.0 billion

Eubiotics - \$37.9 billion

Autoimmune - \$110.0 billion

Antidiabetic - \$48.8 billion



Significant Market Opportunity in Nutritional Markets

Proprietary dried algal biomass as a food or food ingredient



Nutritive compounds found in ZIVO algae support functional food ingredients designed to enhance health in humans and animals

Cultivation model:

- ✓ Presently growing at near-commercial scale in central Peru with low startup cost, sustainability, high yield, continuous harvest
- ✓ Actively working on perfecting the production process for scale up to commercial size ponds
- ✓ Multiple cultivation options – open ponds, photo bioreactors

Product Versatility:

- ✓ Significant levels of protein, micronutrients and non-starch polysaccharides
- ✓ Ease of post-processing
- ✓ Low taste and odor, takes flavorings well
- ✓ Cooperates well with other wet and dry ingredients
- ✓ Shelf stable, does not require refrigeration



Market Opportunity

\$6.3 billion in 2021

Protein supplement market (global)

\$300 million by 2026

US green powder nutritional market





Where ZIVO is Headed – Goals for 2023 and Beyond



Therapeutics

Biotechnology

Molecules
Compounds
Complexes

Poultry Digestive Health

- Prospective licensing or joint development deal
- Continue refinement of poultry product candidates
- Productize, commercialize successful market entry

Immune Modulating Product

- Commercial scale ramp-up of bioactive molecules
- Begin testing in swine and canine models

Intellectual Property Portfolio

- Targeting a strong defendable patent portfolio across the globe

Patents filed. Tested. Ready to license.
An opportunity for major value inflection.

Nutrition

Agricultural Technology

Algal Biomass

Enhanced Products

Strategic Partnerships & Regional Distributors

- Establish regional distributorships
- Form partnerships to create new marketing channels, products, applications

Production & Global Supply Chain

- Recruit agribusinesses globally as licensed growers
- Establish global supply chain with QC compliance
- Expand ZIVO algae production in LATAM

Product Development & Compliance

- Planned launch of whole biomass powder in US, EU
- Expand into uses as a food ingredient

Patents filed. Tested. Market-ready.
An opportunity for immediate revenue.



Leadership Team



John B. Payne – President and CEO

Served on ZIVO's Board since 2013 and Chairman since 2019. He has a significant management experience in publicly-traded healthcare companies and currently also serves as Chairman of the Board for American Humane and as Vice Chairman of the Board of Regents at Ross University School of Medicine and School of Veterinary Medicine.



Harlan L. Miller III, PhD – VP Technology and Global Supply

Dr. Miller is a recognized expert in algal production systems, previously as Sr. Technology Director - Algenol Biotech, LLC. He manages international farm conversions SuperFarm engineering and global tech support, and also directs cultivation science and product development at Ft. Myers research facility.



Keith R. Marchiando – CFO

30 years of functional experience and technical knowledge in corporate finance, planning, and accounting for manufacturing and technology firms. Mr. Marchiando holds broad responsibilities for all finance functions, HR, legal and IT matters. Mr. Marchiando is also corporate secretary and reporting/compliance officer.



Amy E. Steffek, PhD - Director R&D

Over 20 years in life science startups ranging across clinical/analytic research, study coordination and regulatory compliance. Dr. Steffek manages multiple research studies, analyses and reporting of research findings pertaining to the Company's proprietary, naturally derived compounds and bioactive molecules.



William P. Pfund, MS - VP R&D

Wide-ranging career in Big Pharma, life science startups and contract research orgs. Responsible for all R&D strategies aimed at developing and validating novel therapeutics and product candidates from ZIVO's proprietary bioproducts, leveraging specific expertise in analytical, in vitro, and in vivo sciences.



One Natural Source. Numerous Value-Driving Opportunities.

Developing novel therapeutic candidates and nutritional functional food ingredients to power immune health



Near-Term Revenue:

- Via out-licensing IP for a product candidate for the treatment of coccidiosis in poultry
- Commercializing an algae nutritional supplement for the human green powder and vegan protein markets



Long-term Valuation Multiplier:

- Published studies demonstrate an active therapeutics pipeline addressing billion-dollar opportunities in animal and human disease treatment through immune and other novel pathways
- Multi use nutritional ingredient in various foods for animals and humans



Robust and Versatile Products:

- Various commercial applications in animal feed, functional and medical foods, dietary supplements, nutraceuticals and pharmaceuticals

- ✓ Patent-pending use as an immune modulating candidate which may establish a new class of therapeutic products
- ✓ Potentially numerous therapeutic applications across three global mega-markets: human, livestock, and companion animals.